新诺迪斯克公司削减2025年的销售量和利润预测,因为美国销售量和竞争较弱。 Novo Nordisk cuts 2025 sales and profit forecasts due to weaker US sales and competition.

丹麦制药巨头诺沃·诺迪斯克(Novo Nordisk)将2025年的销售预测削减到8-14%,将营业利润削减到10-16%,低于先前的估计,原因是美国药品销售疲软(Wegovy和Ozempic)。 Danish pharmaceutical giant Novo Nordisk has cut its 2025 sales forecast to 8-14% and operating profit to 10-16%, down from previous estimates, due to weaker US sales of its drugs Wegovy and Ozempic. 该公司面临日益激烈的竞争,特别是Eli Lilly的Mounjaro公司的竞争,其市场价值下降600多亿欧元。 The company faces increased competition, particularly from Eli Lilly’s Mounjaro, and has seen its market value drop by over €60 billion. Novo Nordisk还任命了新的首席执行官Maziar Mike Doustdar来应对这些挑战。 Novo Nordisk has also appointed a new CEO, Maziar Mike Doustdar, to address these challenges.